Welcome to our dedicated page for Qscreen AI news (Ticker: PMEDF), a resource for investors and traders seeking the latest updates and insights on Qscreen AI stock.
News about Predictmedix AI Inc. (PMEDF) centers on its development of AI-powered health and safety technology, rapid health screening, and remote patient care platforms. Company announcements describe SmartHealth AI stations and Safe Entry Stations that use proprietary artificial intelligence and multispectral cameras to analyze physiological data patterns, predict vital parameters, and assess issues such as impairment, fatigue, and certain mental illnesses.
Recent releases highlight a multi-vertical growth strategy built around a single Core AI Engine. News items cover the launch of a Clinical-Trial AI Platform designed to simulate and optimize clinical trials, including features like adaptive simulations, patient-site optimization, cost and ROI modeling, and compliance-integrated AI. Other updates describe expansion into consumer digital health through a mobile diabetes screening platform that uses AI-driven facial and biometric analysis via smartphone for non-invasive diabetic risk scoring.
Investors and observers can also find coverage of Predictmedix AI’s capital markets activity, including non-brokered private placements, insider participation, and the stated use of proceeds to advance its AI engine, SmartHealth AI Station certification initiatives, clinical-trial applications, and B2C mobile platforms. Additional news includes participation in international investor conferences and roadshows, as well as selection for a Canadian government trade mission to Mexico to explore commercial opportunities for its health and safety technologies.
Together, these news items provide insight into how Predictmedix AI positions itself at the intersection of AI, quantum-inspired computation, and healthcare, and how it is communicating its technology roadmap, financing plans, and international engagement to the market.
Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) has announced a major upgrade to its Safe Entry Stations, a series of AI-powered health screening tools. The new technology will now include non-invasive blood pressure readings, enhancing the ability to detect cardiovascular diseases, the world's leading cause of death. Existing features include temperature, heart rate, respiratory rate, and oxygen saturation monitoring. The integration of Heart Rate Variability (HRV) analysis is also being introduced, providing early indicators of various diseases. Trials for blood oxygen saturation screening are set to commence in India. Dr. Rahul Kushwah, COO of Predictmedix, emphasized the importance of these developments in making healthcare more efficient and accessible. The company aims to partner with global leaders to establish AI-powered health screening as a standard in medical care.
Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) announced a purchase order from MGM Healthcare, one of India's largest government hospital groups, for five AI-powered Safe Entry Stations. This order, valued at approximately $500,000 CAD over three years, follows a successful clinical study involving 400 patients, validating the effectiveness of the technology. The Safe Entry Stations offer rapid, non-invasive health screenings, enhancing efficiency and patient care in healthcare settings. Dr. Rahul Kushwah emphasized the opportunity for expansion in South Asia and ASEAN countries, where the technology could significantly improve healthcare outcomes.
Predictmedix Inc. (CSE:PMED) has achieved recognition in a major Indonesian newspaper for its AI-powered Safe Entry Station. This technology, validated on over 2,000 individuals, screens key vital signs non-invasively to detect health risks. The University of Raharja is collaborating with the Indonesian government to advance Safe Entry as a medical device. Since the last update, an additional 400 individuals have been screened, reflecting the urgent need for health solutions in Indonesia's 2,500 hospitals. The company also granted 600,000 stock options with an exercise price of $0.15, highlighting its growth initiatives.
Predictmedix Inc. has announced an update on its AI-powered impairment detection technology following a US patent grant for non-invasive detection of impairment from alcohol and/or cannabis. The technology boasts over 90% accuracy using multispectral imaging and speech analysis, with expectations for improved performance due to AI advancements. Targeting global law enforcement and high-risk industries, Predictmedix aims to capitalize on the $39 billion workplace safety market and $22.24 billion drug screening market projected to grow significantly by 2031. The company is focusing on commercializing a mobile app alongside a multispectral imaging camera for impairment detection.
Predictmedix Inc. has received a US patent for its AI-powered technology designed for non-invasive detection of impairment caused by alcohol and cannabis. This innovative system employs multispectral imaging and speech analysis to assess individuals' physiological states rapidly, offering a contactless alternative to traditional tests. The technology is integrated into the Company’s Fit for Duty screening solutions and Safe Entry system, which analyze data in mere seconds. The global workplace safety market is projected to grow significantly, indicating strong market potential for Predictmedix's patented solutions, aimed at improving workplace safety and health assessment.
Predictmedix has initiated the production of an AI-powered mobile application designed to detect impairment from alcohol and cannabis. This innovative tool uses a portable multi-spectral imaging camera and can identify impairment in under 30 seconds with an accuracy exceeding 90%. The product aims to serve law enforcement, transport, and other high-risk sectors. The drug screening market, valued at over $5.2 billion in 2021, is projected to surpass $22 billion by 2030, presenting substantial growth opportunities for Predictmedix. They are also focusing on intellectual property protection for their technology.
Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) has successfully completed a 1600-person clinical study at a leading Indonesian university, aimed at securing regulatory approval for its AI-powered Safe Entry screening device to be classified as a medical device. This classification is crucial for commercialization in Indonesia, which is home to over 280 million people. The study validated the effectiveness of Safe Entry, with the approval process expected to be swift due to its non-invasive nature. This advancement marks a significant milestone for Predictmedix, as it builds credibility and paves the way for future sales opportunities in the ASEAN region.
Predictmedix Inc. has secured a purchase agreement with DefSpace to lease four Safe Entry Stations over a four-year term, generating $2,500 per month per station, totaling approximately $500,000. This deal positions Predictmedix within the defence and aerospace sectors, addressing critical issues such as workforce impairment which impacts productivity and safety. The global workplace safety market is projected to reach $39 billion by 2031, highlighting significant growth potential. The technology facilitates vital sign screenings for alcohol or drug impairment using AI algorithms and multispectral cameras.
Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) announced significant clinical validation for its AI-driven Safe Entry Stations from a major hospital group in India. This confirmation follows a 400-patient study demonstrating the technology's ability to screen for various health conditions non-invasively. Safe Entry Stations utilize multi-spectral imaging to assess vital signs like temperature and heart rate in a matter of seconds, enhancing patient care while alleviating the burdens on healthcare professionals. The system has been deployed for over 18 months at MGM Healthcare, receiving positive evaluations for its accuracy, especially during the peak of the COVID-19 outbreak.
Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) has successfully closed a non-brokered private placement, raising $612,500 by issuing 12,250,000 units at $0.05 per unit. Each unit comprises one common share and one warrant, exercisable at $0.10 for up to two years. The funds will support general operations and technology upgrades. The company also announced the acceptance of its shares for trading on the Frankfurt Stock Exchange under the symbol 3QP, enhancing its liquidity and visibility in Europe. The AI healthcare market is projected to grow significantly, indicating potential growth for Predictmedix.